Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

NCT06413745 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Expression / Amplification in Patients With Biliary Tract Cancer

Interventions

DRUG: SHR-A1811

Sponsor

Jiangsu HengRui Medicine Co., Ltd.